|
1
|
McGuire S: World cancer report 2014.
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lange F, Franz B, Maletzki C, Linnebacher
M, Hühns M and Jaster R: Biological and molecular effects of small
molecule kinase inhibitors on low-passage human colorectal cancer
cell lines. Biomed Res Int. 2014:5686932014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holm T, Cedermark B and Rutqvist LE: Local
recurrence of rectal adenocarcinoma after ‘curative’ surgery with
and without preoperative radiotherapy. Br J Surg. 81:452–455. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park IJ and Yu CS: Current issues in
locally advanced colorectal cancer treated by preoperative
chemoradiotherapy. World J Gastroenterol. 20:2023–2029. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Braendengen M, Tveit KM, Berglund A,
Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K
and Glimelius B: Randomized phase III study comparing preoperative
radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
J Clin Oncol. 26:3687–3694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kao PS, Chang SC, Wang LW, Lee RC, Liang
WY, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS and Lin JK: The
impact of preoperative chemoradiotherapy on advanced low rectal
cancer. J Surg Oncol. 102:771–777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parsons SL, Watson SA, Brown PD, Collins
HM and Steele RJ: Matrix metalloproteinases. Br J Surg. 84:160–166.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zucker S and Vacirca J: Role of matrix
metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis
Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arakaki PA, Marques MR and Santos MC:
MMP-1 polymorphism and its relationship to pathological processes.
J Biosci. 34:313–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murray GI, Duncan ME, O'Neil P, Melvin WT
and Fothergill JE: Matrix metalloproteinase-1 is associated with
poor prognosis in colorectal cancer. Nat Med. 2:461–462. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zinzindohoué F, Lecomte T, Ferraz JM,
Houllier AM, Cugnenc PH, Berger A, Blons H and Laurent-Puig P:
Prognostic significance of MMP-1 and MMP-3 functional promoter
polymorphisms in colorectal cancer. Clin Cancer Res. 11:594–599.
2005.PubMed/NCBI
|
|
15
|
Bendardaf R, Buhmeida A, Ristamäki R,
Syrjänen K and Pyrhönen S: MMP-1 (collagenase-1) expression in
primary colorectal cancer and its metastases. Scand J
Gastroenterol. 42:1473–1478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han G, Wei Z, Lu Z, Cui H, Bai X, Ge H and
Zhang W: Association between matrix metalloproteinase 1 −1607
1G>2G polymorphism and cancer risk: A meta-analysis including
19706 subjects. Int J Clin Exp Med. 7:2992–2999. 2014.PubMed/NCBI
|
|
17
|
Drzymala M, Hawkins M, Henrys A, Bedford
J, Norman A and Tait D: The effect of treatment position, prone or
supine, on dose-volume histograms for pelvic radiotherapy in
patients with rectal cancer. Br J Radiol. 82:321–327. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JY, Kim DY, Kim TH, Park SY, Lee SB,
Shin KH, Pyo H, Kim JY and Cho KH: Intensity-modulated radiotherapy
with a belly board for rectal cancer. Int J Colorectal Dis.
22:373–379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Häfner MF and Debus J: Radiotherapy for
colorectal cancer: Current standards and future perspectives. Visc
Med. 32:172–177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tahara K, Mimori K, Iinuma H, Iwatsuki M,
Yokobori T, Ishii H, Anai H, Kitano S and Mori M: Serum
matrix-metalloproteinase-1 is a bona fide prognostic marker for
colorectal cancer. Ann Surg Oncol. 17:3362–3369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teran BL and Thomas J: Antimycin induces
apoptosis in rapamycin resistant SW620 colorectal cancer cells.
FASEB J. 27:793–798. 2013.PubMed/NCBI
|
|
24
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Langenskiöld M, Ivarsson ML, Holmdahl L,
Falk P, Kåbjörn-Gustafsson C and Angenete E: Intestinal mucosal
MMP-1-a prognostic factor in colon cancer. Scand J Gastroenterol.
48:563–569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nishioka M, Shimada M, Kurita N, Iwata T,
Morimoto S, Yoshikawa K, Higashijima J and Miyatani T: Gene
expression profile can predict pathological response to
preoperative chemoradiotherapy in rectal cancer. Cancer Genomics
Proteomics. 8:87–92. 2011.PubMed/NCBI
|
|
27
|
Artacho-Cordón F, Ríos-Arrabal S, Lara PC,
Artacho-Cordón A, Calvente I and Núñez MI: Matrix
metalloproteinases: Potential therapy to prevent the development of
second malignancies after breast radiotherapy. Surg Oncol.
21:143–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Angenete E, Oresland T, Falk P, Breimer M,
Hultborn R and Ivarsson ML: Preoperative radiotherapy and
extracellular matrix remodeling in rectal mucosa and tumour matrix
metalloproteinases and plasminogen components. Acta Oncol.
48:1144–1151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Supiot S, Gouraud W, Campion LC, Jezéquel
P, Buecher B, Charrier J, Heymann MF, Mahé MA, Rio E and Chérel M:
Early dynamic transcriptomic changes during preoperative
radiotherapy in patients with rectal cancer: A feasibility study.
World J Gastroenterol. 19:3249–3254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jo S, Choi Y, Park SK, Kim JY, Kim HJ, Lee
YH, Oh WY, Cho H and Ahn KJ: Efficacy of dose-escalated
radiotherapy for recurrent colorectal cancer. Ann Coloproctol.
32:66–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sanghera P, Wong DW, McConkey CC, Geh JI
and Hartley A: Chemoradiotherapy for rectal cancer: An updated
analysis of factors affecting pathological response. Clin Oncol (R
Coll Radiol). 20:176–183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun K, Zhang X, Deng H, et al: Effects of
X-ray dose on expression of microRNA-221 and p57~ (kip2) in human
colorectal carcinoma cells. Cancer Res Prev Treat. 40:921–924.
2013.
|
